-DOCSTART- -X- O
Recombinant -X- _ B-Intervention
subvirual -X- _ I-Intervention
particles -X- _ I-Intervention
retain -X- _ O
similar -X- _ O
antigenic -X- _ O
features -X- _ O
of -X- _ O
their -X- _ O
authentic -X- _ O
viral -X- _ O
capsids -X- _ O
and -X- _ O
thus -X- _ O
have -X- _ O
been -X- _ O
applied -X- _ O
as -X- _ O
nonreplicating -X- _ O
subunit -X- _ O
vaccines -X- _ O
against -X- _ O
viral -X- _ O
infection -X- _ O
and -X- _ O
illness. -X- _ O
Additionally -X- _ O
, -X- _ O
the -X- _ O
self-assembled -X- _ O
, -X- _ O
polyvalent -X- _ B-Intervention
subviral -X- _ I-Intervention
particles -X- _ I-Intervention
are -X- _ O
excellent -X- _ O
platforms -X- _ O
to -X- _ O
display -X- _ O
foreign -X- _ O
antigens -X- _ O
for -X- _ O
immune -X- _ O
enhancement -X- _ O
for -X- _ O
vaccine -X- _ O
development. -X- _ O
These -X- _ O
subviral -X- _ B-Outcome
particle- -X- _ I-Outcome
based -X- _ I-Outcome
vaccines -X- _ I-Outcome
are -X- _ I-Outcome
noninfectious -X- _ I-Outcome
and -X- _ I-Outcome
thus -X- _ I-Outcome
safer -X- _ I-Outcome
than -X- _ I-Outcome
the -X- _ I-Outcome
conventional -X- _ I-Outcome
live -X- _ I-Outcome
attenuated -X- _ I-Outcome
and -X- _ I-Outcome
inactivated -X- _ I-Outcome
vaccines. -X- _ I-Outcome
While -X- _ O
several -X- _ O
VLP -X- _ O
vaccines -X- _ O
are -X- _ O
available -X- _ O
in -X- _ O
the -X- _ O
markets -X- _ O
, -X- _ O
numerous -X- _ O
others -X- _ O
, -X- _ O
including -X- _ O
dual -X- _ O
vaccines -X- _ O
against -X- _ O
more -X- _ O
than -X- _ O
one -X- _ O
pathogen -X- _ O
, -X- _ O
are -X- _ O
under -X- _ O
clinical -X- _ O
or -X- _ O
preclinical -X- _ O
development. -X- _ O
This -X- _ O
article -X- _ O
provides -X- _ O
an -X- _ O
update -X- _ O
of -X- _ O
these -X- _ O
efforts -X- _ O
. -X- _ O

